Myeloid Cell InfiltrationSenactivNCT07703774
Effect of Rg1-based Supplementation on Exercise Training-induced Stem Cell Recruitments and Skeletal Muscle Adaptation in Women Aged > 60
A study testing Resistance exercise in people with Myeloid Cell Infiltration, run by University of Taipei.
Trial summary
This study will provide novel insights into the role of bone marrow-derived stem cells in muscle adaptation to long-term exercise and advance our understanding of an Rg-1 based supplement-Senactiv® as a potential intervention for preventing sarcopenia and cognitive decline in older adults. Read more about this study
- Who is it for?
- Ages 20 to 90 yearsHealthy volunteers can take part
- Conditions the study is for
- Myeloid Cell Infiltration
- What is being tested?
- Resistance exercise
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 60 participants
- Where
- No sites listed yet
- Study dates
- 2 Aug 2026to 2 Jan 2029
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 20 to 90 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Must be able to swallow pills
Who cannot join
None listed.
Trial locations and contacts
No sites are listed yet. Contact the study team or a site near you to ask about taking part.
About this study
This study will provide novel insights into the role of bone marrow-derived stem cells in muscle adaptation to long-term exercise and advance our understanding of an Rg-1 based supplement-Senactiv® as a potential intervention for preventing sarcopenia and cognitive decline in older adults.
Read the detailed description
Background: We have recently observed increased mesenchymal stem cells (Stro-1+ MSCs) in exercised skeletal muscle in women > 60 years following consumption of a ginseng-derived Rg1-based supplement (Senactiv®). A substantial proportion of these mobilized stem cells differentiated into neural stem cells (Nestin+). Exercise-induced sex hormone depletion is completely attenuated. Together with our earlier finding that Senactiv® reduced perceived exertion during resistance exercise in young men, these results suggest that the supplement may enhance brain-muscle connection/rewiring to improve performance. This acute, single-dose study raises the important question of whether long-term Senactiv® consumption can augment muscle strength and mass in older women engaged in resistance training, a population at high risk of progressing into sarcopenia.
Study Design: To address this, we will conduct a 12-week, two-arm, randomized, double-blind, placebo-controlled trial. Primary and secondary outcomes will include muscle strength, perceived exertion, muscle mass, grip strength and sitting-rising test, sex hormones, Nestin+ neural stem cells, mitochondria-rich phagocytes (MPO-expressing cells), transcriptomic changes (RNA-seq) focusing on age-related biomarkers, bone marrow-derived cells and cognitive function. Skeletal muscle tissue will be analyzed using minimally invasive micro-biopsy at three time points: pre-exercise baseline, immediately after the first exercise bout (0 h, acute response), and 48 hours after the final training session (long-term adaptation). Cognitive function will be comprehensively assessed using available campus resources.
- Conditions
- Myeloid Cell Infiltration
- Being tested
- Resistance exercise
- Keywords
- Nestin+ cells, Neural stem cells, Acetylcholine receptor
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Resistance exerciseBehavioural
4 sets of 8-RM leg squats
| Study group | Role | What they receive |
|---|---|---|
| Placebo | Placebo comparator | Not described Receives: Behavioral: Resistance exercise |
| Senactiv | Experimental | Rg1-based supplement Receives: Behavioral: Resistance exercise |
What is being measured
The primary outcome is the main question the study is designed to answer.
Bone marrow derived cells in skeletal muscle
Cell markers with bone marrow identity
Measured: * 3 weeks before exercise (baseline) * Immediately after exercise (0 hour) * 1-hour after exercise (1 h) * 24-hour after exercise (24 h)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted14 Jul 2026
- Study start2 Aug 2026 (estimated)
- Primary completion2 Jan 2029 (estimated)
- Study completion2 Jan 2029 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Myeloid Cell InfiltrationStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Randomized controlled trial of Rg1 and Placebo supplementation
- Masking
- Triple blind
- Who is masked
- Participant, Care provider, Outcomes assessor
- Enrolment
- 60 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University of Taipei
- Sponsor type
- University, hospital or other
- Collaborators
- Education University of Hong Kong
- Responsible party
- Principal investigator, Chia-Hua Kuo, University of Taipei
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07703774
- Sponsor's protocol ID
- 2025-2026-0067
- Acronym
- Senactiv
- Status last verified
- Jul 2026
- First submitted
- 9 Jul 2026
- Last updated
- 22 Jul 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 22 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effect of Rg1-based Supplementation on Exercise Training-induced Stem Cell Recruitments and Skeletal Muscle Adaptation in Women Aged > 60
- ClinicalTrials.gov ID
- NCT07703774
- Acronym / sponsor ID
- Senactiv / 2025-2026-0067
- Conditions
- Myeloid Cell Infiltration
- Keywords
- Nestin+ cells, Neural stem cells, Acetylcholine receptor
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 60 participants (estimated)
- Lead sponsor
- University of TaipeiUniversity, hospital or other
- Collaborators
- Education University of Hong Kong
- Study start
- 2 Aug 2026 (estimated)
- Primary completion
- 2 Jan 2029 (estimated)
- Study completion
- 2 Jan 2029 (estimated)
- First posted
- 14 Jul 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study will provide novel insights into the role of bone marrow-derived stem cells in muscle adaptation to long-term exercise and advance our understanding of an Rg-1 based supplement-Senactiv® as a potential intervention for preventing sarcopenia and cognitive decline in older adults.
Detailed description
Background: We have recently observed increased mesenchymal stem cells (Stro-1+ MSCs) in exercised skeletal muscle in women > 60 years following consumption of a ginseng-derived Rg1-based supplement (Senactiv®). A substantial proportion of these mobilized stem cells differentiated into neural stem cells (Nestin+). Exercise-induced sex hormone depletion is completely attenuated. Together with our earlier finding that Senactiv® reduced perceived exertion during resistance exercise in young men, these results suggest that the supplement may enhance brain-muscle connection/rewiring to improve performance. This acute, single-dose study raises the important question of whether long-term Senactiv® consumption can augment muscle strength and mass in older women engaged in resistance training, a population at high risk of progressing into sarcopenia.
Study Design: To address this, we will conduct a 12-week, two-arm, randomized, double-blind, placebo-controlled trial. Primary and secondary outcomes will include muscle strength, perceived exertion, muscle mass, grip strength and sitting-rising test, sex hormones, Nestin+ neural stem cells, mitochondria-rich phagocytes (MPO-expressing cells), transcriptomic changes (RNA-seq) focusing on age-related biomarkers, bone marrow-derived cells and cognitive function. Skeletal muscle tissue will be analyzed using minimally invasive micro-biopsy at three time points: pre-exercise baseline, immediately after the first exercise bout (0 h, acute response), and 48 hours after the final training session (long-term adaptation). Cognitive function will be comprehensively assessed using available campus resources.
Study design
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind (participant, care provider, outcomes assessor)
- Number of arms
- 2
- Model description
- Randomized controlled trial of Rg1 and Placebo supplementation
| Arm | Type | Receives |
|---|---|---|
| Placebo | Placebo comparator | Behavioral: Resistance exercise |
| Senactiv | Experimental | Behavioral: Resistance exerciseRg1-based supplement |
Who may qualify
- Ages
- 20 to 90 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (1 listed)
- Must be able to swallow pills
Key exclusion criteria (0 listed)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Resistance exercise4 sets of 8-RM leg squats | Behavioural | Placebo, Senactiv |
Primary outcome
Bone marrow derived cells in skeletal muscle
Time frame: * 3 weeks before exercise (baseline) * Immediately after exercise (0 hour) * 1-hour after exercise (1 h) * 24-hour after exercise (24 h)
Cell markers with bone marrow identity
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 22 Jul 2026.
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Questions about this trial
What is this clinical trial studying?
A study testing Resistance exercise in people with Myeloid Cell Infiltration, run by University of Taipei.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 0 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 22 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Chia-Hua Kuo, PhD (+85263057921, kuochiahua@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Bone marrow derived cells in skeletal muscle (time frame: * 3 weeks before exercise (baseline) * Immediately after exercise (0 hour) * 1-hour after exercise (1 h) * 24-hour after exercise (24 h)). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 Jul 2026; AzTrials last refreshed its copy on 1 Nov 2026.